US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Joseph W. Hauser, President of Trauma and Deformity Correction at Orthopediatrics Corp (NASDAQ:KIDS), recently sold a portion of his holdings in the company. According to a recent SEC filing, Hauser sold 5,300 shares of common stock on March 18 at a price of $24.86 per share, amounting to a total transaction value of $131,758. The stock currently trades at $25.28, slightly above the insider sale price. According to InvestingPro, the company has a market capitalization of approximately $615 million.
The shares sold were intended to satisfy tax withholding obligations upon the vesting of restricted shares. Following this transaction, Hauser holds 137,663 shares, which includes restricted stock awards totaling 109,722 shares. InvestingPro data shows the company maintains strong liquidity with a current ratio of 6.98 and operates with a moderate debt level.
Orthopediatrics, known for its focus on pediatric orthopedic devices, continues to maintain its position in the surgical and medical instruments industry. The company demonstrated robust revenue growth of 37.7% in the last twelve months, with analysts setting a consensus price target ranging from $26 to $50. Get detailed insights and 12+ additional ProTips with InvestingPro’s comprehensive research report.
In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, showing a larger-than-expected loss with an EPS of -$0.69, missing the forecasted -$0.30. However, the company’s revenue reached $52.7 million, surpassing expectations of $50.72 million and marking a 40% year-over-year increase. The company expects revenue growth of 15-18% in 2025, aiming for its first positive free cash flow by the fourth quarter of 2025. Stifel analysts adjusted the company’s stock price target to $32 from $40, maintaining a Buy rating due to a positive outlook from the earnings call. The company plans to expand its Specialty Bracing franchise and launch new products like the PNP Tibia and DF2 Fracture Brace in 2025. Despite the EPS miss, OrthoPediatrics remains optimistic about future growth, with plans to enhance its product offerings and expand its market presence. The company also highlighted its strongest U.S. Trauma business performance to date, supported by ongoing set deployments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.